To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The widespread evolution, validation, and clinical utilization of molecular technologies, such as fluorescence in situ hybridization and next-generation sequencing has enabled the identification of a number of prognostic and predictive biomarkers for...Continue Reading

Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM Subclonal TP53 copy number is associated with MM prognosis Download here – Multiple Myeloma Research Review Issue 29Continue Reading

Research Review Multiple Myeloma Summit Highlights include:  High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment Burden of MM in NZ Download hereContinue Reading

Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria St Wellington RSVP by Friday 7 December to contact@multiplemyeloma.org.nzContinue Reading

Issue 28 of Multiple Myeloma Research Review. Highlights include:  Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to Pri-17-92 inhibition Identification of novel mutational drivers reveals oncogene dependencies in MM Patient reported health-related Q0L from TOURMALINE-MM1 Download hereContinue Reading

INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at Russell McVeagh, Level 24, Dimension Data House, 157 Lambton Quay RSVP by Friday 2 March to contact@multiplemyeloma.org.nz    Continue Reading

INVITATION Patient Seminar: What’s New in Myeloma Treatment: a New Zealand Perspective  with Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson on 28 February, from 7 – 9pm (Network from 6.30pm) at North Shore Hospital Auditorium – Whenua Pupuke, Auckland RSVP to: contact@multiplemyeloma.org.nz  Continue Reading

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients The duration of the study for the patients will include a period for screening of up to 3 weeks. Patients will continue study treatment until disease progression, unacceptable adverse reaction, patients’ wish or other reason of...Continue Reading

Issue 24 of Multiple Myeloma Research Review.   Highlights include: Is MRD the best predictor of response? ctDNA and risk of distant relapse. Cardiac safety of bortezomib. Cytogenic evolution in relapsed MM. Download hereContinue Reading